Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer - PubMed (original) (raw)

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer

Edward J Tanner et al. Gynecol Oncol. 2012 Jan.

Abstract

Objective: Adjuvant intraperitoneal (IP) platinum-based chemotherapy has been shown to improve outcome for patients with advanced ovarian cancer. We hypothesize that patients who have received adjuvant IP chemotherapy more commonly recur first at extraperitoneal sites than patients who have received adjuvant intravenous (IV) chemotherapy.

Methods: Patients with newly diagnosed stage IIIC optimally debulked serous ovarian cancer were identified from institutional databases. Patterns of recurrence were compared between patients who received IV and IP chemotherapy using standard two-sided statistical tests.

Results: Of the 104 patients who met inclusion criteria, 60 received IV chemotherapy and 44 received IP chemotherapy. Patients in the IV group had a first recurrence more commonly in the lower abdomen or pelvis than the IP group. Patients in the IP group more commonly recurred in the upper abdomen and extra-abdominal lymph nodes. More patients in the IP group than the IV group recurred at extra-abdominal sites (45.5% versus 23.3%, P=0.018).

Conclusions: Patients receiving adjuvant IP chemotherapy are less likely to first recur in the lower abdomen or pelvis and more likely to recur outside of the abdominal cavity. The data suggest that IP chemotherapy is highly effective in the anatomic areas of peritoneal distribution.

PubMed Disclaimer

Cited by

Should We Abandon Intraperitoneal Chemotherapy in the Treatment of Advanced Ovarian Cancer? A Meta-Analysis.
Climent MT, Serra A, Balaguer C, Llueca A. Climent MT, et al. J Pers Med. 2023 Nov 23;13(12):1636. doi: 10.3390/jpm13121636. J Pers Med. 2023. PMID: 38138863 Free PMC article. Review.
Pigment epithelium-derived factor promotes peritoneal dissemination of ovarian cancer through induction of immunosuppressive macrophages.
Ueno S, Sudo T, Saya H, Sugihara E. Ueno S, et al. Commun Biol. 2022 Sep 2;5(1):904. doi: 10.1038/s42003-022-03837-4. Commun Biol. 2022. PMID: 36056141 Free PMC article.
Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning.
Laios A, Katsenou A, Tan YS, Johnson R, Otify M, Kaufmann A, Munot S, Thangavelu A, Hutson R, Broadhead T, Theophilou G, Nugent D, De Jong D. Laios A, et al. Cancer Control. 2021 Jan-Dec;28:10732748211044678. doi: 10.1177/10732748211044678. Cancer Control. 2021. PMID: 34693730 Free PMC article.
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, Henson M, Iasonos A, Zhou Q, Sarasohn DM, Gallagher J, Kravetz S, Zamarin D, Makker V, Sabbatini PJ, Tew WP, Aghajanian C, Konner JA. Cadoo KA, et al. Gynecol Oncol. 2020 Apr;157(1):214-221. doi: 10.1016/j.ygyno.2020.01.018. Epub 2020 Jan 17. Gynecol Oncol. 2020. PMID: 31959492 Free PMC article. Clinical Trial.
Ovarian cancer: Current status and strategies for improving therapeutic outcomes.
Chandra A, Pius C, Nabeel M, Nair M, Vishwanatha JK, Ahmad S, Basha R. Chandra A, et al. Cancer Med. 2019 Nov;8(16):7018-7031. doi: 10.1002/cam4.2560. Epub 2019 Sep 27. Cancer Med. 2019. PMID: 31560828 Free PMC article. Review.

Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer - PubMed (original) (raw)